Skip to main content
. 2024 Mar 20;12:1278046. doi: 10.3389/fpubh.2024.1278046

Table 3.

Patient therapy and clinical outcome of patients admitted with COVID-19 diagnosis in Qatar (N = 1,560).

ICU admitted (n = 780) Non-ICU admitted (n = 780) p-value
Medications during hospitalization, n (%)

  • Azithromycin

  • Hydroxychloroquine

  • Lopinavir/ritonavir

  • Darunavir/cobicistat

  • Tocilizumab

  • Ribavirin

  • Plasma protein fraction

  • Oseltamivir

  • ACEI/ARB

  • NSAID

  • Methylprednisolone

    Vasopressor

 761 (97.6%)
750 (96.2%)
381 (48.8%)
55 (7.1%)
514 (65.9%)
90 (11.5%)
132 (16.9%)
615 (78.8%)
174 (22.3%)
50 (6.4%)
615 (78.8%)
134 (17.2%)		 622 (79.7%)
674 (86.4%)
137 (17.6%)
25 (3.2%)
4 (0.5%)
5 (0.6%)
0
521 (66.8%)
133 (17.1%)
24 (3.1%)
6 (0.8%)
0		 <0.001
<0.001
<0.001
0.001
<0.001
<0.001
<0.001
<0.001
0.009
<0.001
<0.001
<0.001
In hospital co-infection, n (%)

  • Bacterial

  • Viral

  • Fungal

 319 (40.9%)
247 (31.7%)
10 (1.3%)
199 (25.5%)		 20 (2.6%)
16 (2.1%)
3 (0.4%)
1 (0.1%)		 <0.001
<0.001
0.051
<0.001
Length of stay in hospital [days], median (IQR) 22 (15) 5 (7) <0.001§
Length of stay in ICU [days], median (IQR) 8 (9) NA
Clinical Outcome, n (%)

  • Discharged from ICU and remained in Hospital

    Discharged Home

  • Still in the ICU

  • Died

  • 29 (3.7%)

  • 636 (81.5%)

    9 (1.2%)

    106 (13.6%)

  • 0

    780 (100%)

  • 0

  • 0

 <0.001

§p-value obtained using Mann–Whitney test; p-value obtained using Chi-square test; ICU, intensive care unit; NSAID, Non-steroidal anti-inflammatory drugs; ACEI, Angiotensin-converting-enzyme inhibitors; ARB, Angiotensin II Receptor Blockers; NA, Not applicable.